Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Genentech |
---|---|
Information provided by: | Genentech |
ClinicalTrials.gov Identifier: | NCT00058552 |
The purpose of this study is to determine if the study drug pertuzumab is effective in treating patients with advanced ovarian cancer that is refractory to, or has recurred following, prior chemotherapy.
Condition | Intervention | Phase |
---|---|---|
Ovarian Cancer |
Drug: Pertuzumab (rhuMAb 2C4) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | A Phase II, Open-Label, Multicenter Study to Evaluate the Effect of Tumor-Based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced, Refractory or Recurrent Ovarian Cancer |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | TOC2689g |
Study First Received: | April 8, 2003 |
Last Updated: | December 22, 2007 |
ClinicalTrials.gov Identifier: | NCT00058552 |
Health Authority: | United States: Food and Drug Administration |
Advanced, refractory, or recurrent ovarian cancer |
Genital Diseases, Female Ovarian cancer Ovarian Neoplasms Gonadal Disorders Genital Neoplasms, Female Endocrine System Diseases |
Urogenital Neoplasms Endocrinopathy Ovarian Diseases Recurrence Endocrine Gland Neoplasms |
Neoplasms Neoplasms by Site Adnexal Diseases |